Journal Information
Vol. 99. Issue 7.
Pages 560-564 (September 2008)
Share
Share
Download PDF
More article options
Vol. 99. Issue 7.
Pages 560-564 (September 2008)
Case report
Full text access
Autologous Hematopoietic Stem Cell Transplantation Followed by Oral Bexarotene in a Patient With Advanced Mycosis Fungoides
Trasplante Autólogo de Progenitores Hematopoyéticos Seguido de Bexaroteno Oral en Paciente Con Micosis Fungoide Avanzada
Visits
5711
S. Pérez-Barrioa,
Corresponding author
spbarrio@hotmail.com

Correspondence: Hospital de Cruces, Servicio de Dermatología, Polígono de Cruces, s/n, 48903 Baracaldo, Vizcaya, Spain.
, R. Izua, J.C. García-Ruizb, E. Aceboa, Z. Martínez de Lagrána, J.L. Díaz-Péreza
a Servicio de Dermatología, Hospital de Cruces. Baracaldo, Vizcaya, Spain
b Servicio de Hematología, Hospital de Cruces. Baracaldo, Vizcaya, Spain
This item has received
Article information
Abstract

We describe the case of a 17-year-old patient with rapidly progressing and aggressive mycosis fungoides, with multiple cutaneous tumors and large cell transformation. She was initially treated with 3 cycles of high-dose chemotherapy with mega-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) without response, leading to the decision to undertake autologous hematopoietic stem cell transplantation. Partial remission of the disease was achieved with this treatment and subsequent introduction of oral bexarotene led to complete remission, which has been maintained for more than 3 years with good tolerance of oral therapy. We discuss the advantages and disadvantages of autologous hematopoietic stem cell transplantation and the use of oral bexarotene.

Key words:
autologous hematopoietic stem cell transplant
bexarotene
cutaneous T-cell lymphoma
mycosis fungoides
Resumen

Exponemos el caso de una paciente de 17 años que presentó una micosis fungoide de evolución rápida y agresiva, con múltiples tumores cutáneos y transformación fenotípica celular a linfoma de células grandes. Fue tratada inicialmente con 3 ciclos de quimioterapia en dosis altas (MEGA-CHOP) sin respuesta, por lo que se decidió realizar un trasplante autólogo de progenitores hematopoyéticos. Este tratamiento consiguió una remisión parcial de la enfermedad, y con la posterior introducción del bexaroteno oral se logró la remisión completa, que se ha mantenido durante más de 3 años con muy buena tolerancia al bexaroteno oral.

Analizamos las ventajas y desventajas de la utilización del trasplante autólogo de progenitores hematopoyéticos y del uso de bexaroteno oral.

Palabras clave:
trasplante autólogo de precursores hematopoyéticos
bexaroteno
linfoma cutáneo de células T
micosis fungoide
Full text is only aviable in PDF
References
[1.]
S.J. Whittaker, J.R. Marsden, M. Spittle, R. Russell Jones.
British Association of Dermatologists; U.K. Cutaneous Lymphoma Group. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas.
Br J Dermatol, 149 (2003), pp. 1095-1107
[2.]
H.M. Prince, C. McCormack, G. Ryan, R. O’Keefe, J.F. Seymour, C. Baker.
Management of the primary cutaneous lymphomas.
Australas J Dermatol, 44 (2003), pp. 227-242
[3.]
J. Guitart, S.C. Wickless, Y. Oyama, T.M. Kuzel, S.T. Rosen, A. Traynor, et al.
Long-term remission after allogenic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma.
Arch Dermatol, 138 (2002), pp. 1359-1365
[4.]
A. Molina, J. Zain, D.A. Arber, M. Angelopolou, M. O’Donnell, J. Murata-Collins, et al.
Durable clinical, cytogenetic, and molecular remissions after allogenic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides.
J Clin Oncol, 23 (2005), pp. 6163-6171
[5.]
O. Lasa, R. Izu, E. Acebo, P. Eguino, J.L. Díaz-Pérez.
Tratamiento de linfomas cutáneos de células T con bexaroteno.
Actas Dermosifiliogr, 96 (2005), pp. 669-673
[6.]
F. Singh, M.G. Lebohl.
Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
J Am Acad Dermatol, 51 (2004), pp. 570-573
[7.]
K.S. Mc Ginnis, M. Shapiro, C.C. Vittorio, A.H. Rook, J.M. Junkins-Hopkins.
Psoralen plus long-wave UVA (PUVA) and bexarotene therapy. An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T cell lymphoma.
Arch Dermatol, 39 (2003), pp. 771-775
[8.]
P.L. Ortiz-Romero, M.E. Sánchez-Largo, H. Sanz, D. García-Romero, B. Rosales, R. Valverde, et al.
Tratamiento de micosis fungoide con PUVA más bexaroteno.
Actas Dermosifiliogr, 97 (2006), pp. 311-318
[9.]
K.S. Mc Ginnis, J.M. Junkins-Hopkins, G. Crawford, M. Shapiro, A.H. Rook, C.C. Vittorio.
Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
J Am Acad Dermatol, 50 (2004), pp. 375-379
[10.]
K.S. Mc Ginnis, R. Ubriani, S. Newton, J.M. Junkins-Hopkins, C.C. Vittorio, E.J. Kim, et al.
The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome.
Arch Dermatol, 141 (2005), pp. 1176-1178
[11.]
G. Gorgun, F. Foss.
Immunomodulatory effects of RXR rexinoids: modulation of high IL-2R expression enhances susceptibility to denileukin diftitox.
Blood, 100 (2002), pp. 1399-1403
[12.]
F. Foss, M.F. Demierre, G. DiVenuti.
A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.
Blood, 106 (2005), pp. 454-457
Copyright © 2008. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
Download PDF
Idiomas
Actas Dermo-Sifiliográficas
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?